Physician profile
Michael E Pohlod
NPI 1316904774
$4,700.75
in general payments reported to CMS, 2019-2025
16 companies · $616 in 2025
The $616 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $313 · 2021: $687 · 2022: $867 · 2023: $932 · 2024: $927 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,474.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $950.16 | 2022-2025 | |
| Alcon Vision LLC | $897.03 | 2019-2025 | Rocklatan, Lensx, Tryptyr |
| Sun Pharmaceutical Industries INC. | $399.23 | 2021-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $369.29 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $316.93 | 2019-2021 | |
| Rxsight INC | $313.38 | 2022-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Johnson & Johnson Surgical Vision, INC. | $299.74 | 2020-2023 | Tecnis Iol |
| Amgen INC. | $238.71 | 2024-2025 | Tepezza |
| Allergan, INC. | $220.01 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $212.96 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $212.25 | 2022-2023 | Miebo, Xiidra, Vyzulta |
| Harrow Eye, LLC | $132.26 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $88.49 | 2022-2023 | Tyrvaya |
| Biotissue Holdings INC. | $22.48 | 2024 | |
| Rayner Intraocular Lenses Limited | $14.52 | 2023 | Omidria, Rayone Aspheric, Rayone Emv |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pohlod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.